Nom du produit:(3AR,5R,6aS)-5-((R)-2,2-Dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyldihydrofuro[2,3-d][1,3]dioxol-6(3aH)-one

IUPAC Name:(3aR,5R,6aS)-5-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyl-tetrahydro-2H-furo[2,3-d][1,3]dioxol-6-one

CAS:2847-00-9
Formule moléculaire:C12H18O6
Pureté:95%
Numéro de catalogue:CM196256
Poids moléculaire:258.27

Unité d'emballage Stock disponible Prix($) Quantité
CM196256-1g in stock șșŭ
CM196256-5g in stock ŭƏƻ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:2847-00-9
Formule moléculaire:C12H18O6
Point de fusion:-
Code SMILES:O=C1[C@@H]([C@@H]2OC(C)(C)OC2)O[C@]3([H])OC(C)(C)O[C@@]31[H]
Densité:
Numéro de catalogue:CM196256
Poids moléculaire:258.27
Point d'ébullition:349.8°C at 760 mmHg
N° Mdl:MFCD00040456
Stockage:Store at 2-8°C.

Category Infos

Carbohydrates
Carbohydrates are polyhydroxy aldehydes (aldoses) or polyhydroxy ketones (ketoses) composed of C, H and O, or form polyhydroxy aldehydes or ketones upon hydrolysis. Carbohydrates come in the form of monosaccharides, disaccharides, oligosaccharides and polysaccharides. The simplest sugars, monosaccharides and disaccharides, consist of one or two monosaccharide units. Oligosaccharides are generally classified as carbohydrates containing 3-10 monosaccharide units. Polysaccharides contain more than 10 monosaccharide units and can be quite large. Glucose is an aldose, the most important monosaccharide in the body, used by cells as fuel. Other aldohexoses are galactose and mannose, which form part of complex molecules. Fructose is a ketohexose sugar, while ribose is the most important aldose pentose sugar and a component of RNA.
best carbohydrate supplement
Looking for best carbohydrate supplement? We are waiting to create business relationship with you.

Column Infos

Islatravir and Lenacapavir
Gilead and Merck announced results from the Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class , long-acting HIV capsid inhibitor. At 24 weeks, the novel investigational combination maintained a high rate (94.2%) of viral suppression (HIV-1 RNA <50 copies/mL), which is a secondary endpoint of the study. Results of the primary endpoint (HIV-1 RNA ≥50 copies/mL (c/mL) showed that one participant (1.9%) treated with islatravir and lenacapavir had a viral load of >50 copies/mL at Week 24;the participant later suppressed on islatravir and lenacapavir at Week 30.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

Related Products